General Information
Deucravacitinib is a Tyrosine Kinase 2 Inhibitor. The mechanism of action of deucravacitinib is as a Tyrosine Kinase 2 Inhibitor. Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.
About the API
Systematic name
6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
Trade name(s)
Sotyktu
Technology
Synthetic
Molecular Formula
C20H22N8O3
Molecular Weight
425.5 g/mol
Therapeutic category
Dermatology